B Freundlich

3.8k total citations · 1 hit paper
46 papers, 3.1k citations indexed

About

B Freundlich is a scholar working on Rheumatology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, B Freundlich has authored 46 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 13 papers in Pathology and Forensic Medicine and 10 papers in Hematology. Recurrent topics in B Freundlich's work include Rheumatoid Arthritis Research and Therapies (20 papers), Spondyloarthritis Studies and Treatments (12 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). B Freundlich is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Spondyloarthritis Studies and Treatments (12 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). B Freundlich collaborates with scholars based in United States, Germany and United Kingdom. B Freundlich's co-authors include Sergio A. Jiménez, Jack A. Elias, J. Rosenbloom, Gary H. Lyman, Ann Alexis Prestrud, Mark R. Somerfield, Gary R. Morrow, Petra Feyer, Mark G. Kris and Rebecca Clark-Snow and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

B Freundlich

45 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

2011 827 citations Ethan Basch, Ann Alexis Prestrud et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B Freundlich United States	25	1.1k	809	750	521	410	46	3.1k
Francesco Trotta Italy	36	1.9k 1.7×	891 1.1×	535 0.7×	516 1.0×	511 1.2×	154	3.6k
Alexandros A. Drosos Greece	35	2.0k 1.9×	1.0k 1.2×	528 0.7×	584 1.1×	907 2.2×	127	4.2k
Luis J. Jara Mexico	37	2.0k 1.8×	1.2k 1.5×	372 0.5×	361 0.7×	201 0.5×	122	3.7k
S Todesco Italy	32	2.0k 1.9×	1.0k 1.3×	392 0.5×	501 1.0×	259 0.6×	133	3.7k
Torkell Ellingsen Denmark	30	1.7k 1.5×	668 0.8×	790 1.1×	501 1.0×	361 0.9×	142	3.8k
Roberta Priori Italy	37	1.3k 1.2×	885 1.1×	788 1.1×	562 1.1×	1.4k 3.4×	158	3.9k
Nemanja Damjanov Serbia	23	986 0.9×	410 0.5×	348 0.5×	433 0.8×	255 0.6×	95	2.3k
Paola Di Benedetto Italy	32	574 0.5×	716 0.9×	438 0.6×	584 1.1×	300 0.7×	70	2.7k
G Pasero Italy	29	2.7k 2.5×	1.1k 1.3×	387 0.5×	777 1.5×	216 0.5×	117	4.9k
Benoît Le Goff France	28	883 0.8×	873 1.1×	508 0.7×	250 0.5×	154 0.4×	161	2.9k

Countries citing papers authored by B Freundlich

Since Specialization

Citations

This map shows the geographic impact of B Freundlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B Freundlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B Freundlich more than expected).

Fields of papers citing papers by B Freundlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B Freundlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B Freundlich. The network helps show where B Freundlich may publish in the future.

Co-authorship network of co-authors of B Freundlich

This figure shows the co-authorship network connecting the top 25 collaborators of B Freundlich. A scholar is included among the top collaborators of B Freundlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B Freundlich. B Freundlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Basch, Ethan, Ann Alexis Prestrud, Paul J. Hesketh, et al.. (2011). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 29(31). 4189–4198. 827 indexed citations breakdown →

Hermann, Kay‐Geert, Hildrun Haibel, C Althoff, et al.. (2011). Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Annals of the Rheumatic Diseases. 70(4). 590–596. 197 indexed citations

Song, In‐Ho, Kay‐Geert Hermann, Hildrun Haibel, et al.. (2011). Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Annals of the Rheumatic Diseases. 70(7). 1257–1263. 98 indexed citations

Gniadecki, Robert, Deborah Robertson, C. Molta, et al.. (2011). Self‐reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. Journal of the European Academy of Dermatology and Venereology. 26(11). 1436–1443. 59 indexed citations

Zhang, Wei, Hongyu Sun, Paul Emery, et al.. (2011). Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis?. Lara D. Veeken. 51(2). 270–274. 12 indexed citations

Kekow, J., Robert J. Moots, Rezaul Karim Khandker, et al.. (2010). Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Lara D. Veeken. 50(2). 401–409. 105 indexed citations

Martín‐Mola, E., J. Sieper, Marjatta Leirisalo‐Repo, et al.. (2010). Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.. PubMed. 28(2). 238–45. 38 indexed citations

Sterry, Wolfram, J P Ortonne, Bruce Kirkham, et al.. (2010). Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 340(feb02 2). c147–c147. 186 indexed citations

Ortonne, J.‐P., Alain Taı̈eb, Anthony D. Ormerod, et al.. (2009). Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. British Journal of Dermatology. 161(5). 1190–1195. 53 indexed citations

10.

Emery, Paul, Patrick Durez, F C Breedveld, et al.. (2008). Clinical remission, radiographic non-progression, and normalized function with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis: 1-year results of the COMET trial. Digital Access to Libraries. 58(9). 1 indexed citations

11.

Heijde, Désirée van der, Cătălin Codreanu, E. Martín Mola, et al.. (2008). Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Annals of the Rheumatic Diseases. 68(7). 1113–1118. 14 indexed citations

12.

Kavanaugh, Arthur, et al.. (2008). Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Annals of the Rheumatic Diseases. 67(10). 1444–1447. 34 indexed citations

13.

Heijde, D. van der, E. Martín Mola, Reijo Luukkainen, et al.. (2006). The Addition of Etanercept to Methotrexate and Methotrexate to Etanercept Monotherapies Improves Clinical Efficacy in Ra Patients Despite Low-Moderate Disease Activity at Baseline: Results of the TEMPO Extension Trial (Year 4). JCR Journal of Clinical Rheumatology. 12(Supplement). S49–S50. 1 indexed citations

14.

Freundlich, B, et al.. (1996). Monocyte/Macrophage Infiltrates in the Salivary Glands of Women with Silicone Breast Implants. Current topics in microbiology and immunology. 210. 323–326. 1 indexed citations

15.

Weinberg, Jeffrey S., et al.. (1993). Bilateral periorbital edema in systemic lupus erythematosus.. PubMed. 20(12). 2158–60. 10 indexed citations

16.

Ostrov, Barbara E., et al.. (1992). Knee contractures as the presenting manifestation of scleroderma.. Annals of the Rheumatic Diseases. 51(6). 810–811. 3 indexed citations

17.

Sampson, Phyllis, Carolyn L. Rochester, B Freundlich, & Jack A. Elias. (1992). Cytokine regulation of human lung fibroblast hyaluronan (hyaluronic acid) production. Evidence for cytokine-regulated hyaluronan (hyaluronic acid) degradation and human lung fibroblast-derived hyaluronidase.. Journal of Clinical Investigation. 90(4). 1492–1503. 124 indexed citations

18.

Freundlich, B, et al.. (1990). Treatment of autoimmune disease with extracorporeal photochemotherapy: progressive systemic sclerosis.. PubMed. 62(6). 639–45. 40 indexed citations

19.

Freundlich, B & Sergio A. Jiménez. (1987). Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.. PubMed Central. 69(2). 375–84. 44 indexed citations

20.

Elias, Jack A., et al.. (1987). Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor.. The Journal of Immunology. 138(11). 3812–3816. 208 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact